AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...
Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no ...
The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria ...
Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...
It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...
Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...
With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is enjoying more clarity from the U.S. government now than the same time last year. But several ...
The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback